Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLYX

Polaryx Therapeutics Inc

May 29 • 04:00PM ET

3.27

+0.22 7.21 %

Healthcare • Biotechnology • USA • Micro • NASD

May 28, 9:05 AMPolaryx Therapeutics closes $10 million PIPE equity financing at average $4.00 per share to fund Phase 2 SOTERIA trial

Peers: KPTI CAMP CNTN CNTX IFRX RNA TLSA UNCY MGNX TENX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	91.81%	Shs Outstand	47.34M	Perf Week	-17.01%
Market Cap	154.80M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.21%	Shs Float	3.88M	Perf Month	-37.36%
Enterprise Value	151.72M	PEG	-	EPS next Q	-0.02	Inst Own	4.79%	Short Float	4.64%	Perf Quarter	7.21%
Income	-6.48M	P/S	-	EPS this Y	40.00%	Inst Trans	54.37%	Short Ratio	0.19	Perf Half Y	-
Sales	0.00M	P/B	62.23	EPS next Y	-133.33%	ROA	-163.15%	Short Interest	0.18M	Perf YTD	-90.66%
Book/sh	0.05	P/C	50.26	EPS next 5Y	-	ROE	-192.17%	52W High	48.91 -93.31%	Perf Year	-
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	-54.22% -	ROIC	-260.33%	52W Low	2.07 57.97%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	31.09% 20.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	16.88%	Oper. Margin	-	ATR (14)	0.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	49.48%	SMA20	-6.68%	Beta	-	Target Price	10.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-34.62%	Rel Volume	0.60	Prev Close	3.05
Employees	11	LT Debt/Eq	0.00	Earnings	Feb 25	SMA200	-41.35%	Avg Volume	934.55K	Price	3.27
IPO	Feb 02, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	563,362	Change	7.21%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-26	Initiated	Maxim Group	Buy	$10

May-28-26 08:30AM	Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial (GlobeNewswire) +21.51%
May-14-26 09:15AM	Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards (GlobeNewswire)
Apr-23-26 08:30AM	Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference (GlobeNewswire)
Apr-21-26 08:30AM	Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial (GlobeNewswire) -7.54%
Apr-15-26 09:15AM	Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care (GlobeNewswire)
08:30AM	Loading…
Apr-01-26 08:30AM	Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-26 08:30AM	Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) (GlobeNewswire)
Mar-12-26 08:30AM	Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events (GlobeNewswire) -19.27%
Feb-27-26 08:30AM	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders (GlobeNewswire)
Feb-17-26 10:26AM	Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
08:30AM	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)
Feb-10-26 08:30AM	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium (GlobeNewswire) -24.11%
Feb-05-26 08:30AM	Polaryx Therapeutics Welcomes New Members of the Board of Directors (GlobeNewswire) -28.89%
Feb-04-26 08:40AM	Polaryx to present late-breaker data related to Soteria ahead of trial (TipRanks)
Feb-03-26 08:30AM	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch (GlobeNewswire) -37.29%
08:30AM	Loading…
Feb-02-26 08:30AM	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" (GlobeNewswire)

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

L.L.M.Mr. Alex Yang J.D.

CFO & DirectorMr. G. Michael Landis CPA

Chief Investment OfficerMr. Andrew John O

Ph.D.Dr. Shrijay Vijayan M.B.A.

Ph.D.Mr. Wuxin Zhu P.M.P.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yang Alex Keun Mo	Chief Executive Officer	May 27 '26	Buy	4.07	88,453	360,004	24,233,249	May 28 08:00 PM
Landis G. Michael	Chief Financial Officer	Feb 18 '26	Buy	2.79	2,867	7,991	228,225	Feb 20 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLYX

Polaryx Therapeutics Inc

Upgrade your Finviz experience